MedTrace Logo

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

NCT00003811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2013-07-04

No results posted yet for this study

Summary

RATIONALE: Chemotherapy drugs use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of high-dose cisplatin, etoposide, and bleomycin plus amifostine in treating children who have malignant germ cell tumors.

Conditions

  • Childhood Germ Cell Tumor
  • Drug/Agent Toxicity by Tissue/Organ
  • Extragonadal Germ Cell Tumor
  • Ovarian Cancer

Interventions

BIOLOGICAL

bleomycin sulfate

DRUG

amifostine trihydrate

DRUG

cisplatin

DRUG

etoposide

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Neyssa M. Marina, MD · Stanford University

Study Design

Purpose
TREATMENT

Eligibility

Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2004-10-31
Completion
2007-09-30

Countries

  • United States
  • Australia
  • Canada
  • Netherlands
  • Puerto Rico
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003811 on ClinicalTrials.gov